"it lists ABSSSI as an antibiotic space that has low unmet need and high competition in the space."
Indeed it does. The second thing it listed was differentiation: "It is very important for an asset to have strong differentiation from competing products and also a high perceived unmet need. The anti-infective industry has lacked both in recent years in antibiotics."
Weren't you under the impression that B-ABSSSI's ability to overcome the antibiotic resistance issue was its primary source of differentiation? That it was the shopworn "game changer" and that that feature could address the unmet need issue that resulted from high competition?
News 
Market Data 
Discover 
